ML351

ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2[1]. ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D[2].

Product Specifications

CAS Number

[847163-28-4]

UNSPSC

12352005

Hazard Statement

H301

Target

Lipoxygenase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ml351.html

Purity

99.16

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N#CC1=C(NC)OC(C2=C3C=CC=CC3=CC=C2)=N1

Molecular Formula

C15H11N3O

Molecular Weight

249.27

Precautions

H301

References & Citations

[1]Thomas Gaberel, et al. Impact of 12/15-Lipoxygenase on Brain Injury After Subarachnoid Hemorrhage. Stroke. 2019 Feb;50 (2) :520-523.|[2]Ganesha Rai, et al. Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1|[3]Marimar Hernandez-Perez, et al. Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes. Diabetes. 2017 Nov;66 (11) :2875-2887.